Article Link: FDA Approves Quzyttir (cetirizine) Injection for the Treatment of Acute Urticaria October 11, 2019 – The U.S. Food an...
FDA Approves Beovu (brolucizumab-dbll) for the Treatment of Wet Age-Related Macular Degeneration (AMD)
Article Link: FDA Approves Beovu (brolucizumab-dbll) for the Treatment of Wet Age-Related Macular Degeneration (AMD) EAST HANOVER, N.J., ...
FDA Approves Scenesse (afamelanotide) for Erythropoietic Protoporphyria
Article Link: FDA Approves Scenesse (afamelanotide) for Erythropoietic Protoporphyria October 08, 2019 — The U.S. Food and Drug Adm...
FDA Approves Scenesse (afamelanotide) for Prevention of Phototoxicity in Erythropoietic Protoporphyria
Article Link: FDA Approves Scenesse (afamelanotide) for Prevention of Phototoxicity in Erythropoietic Protoporphyria October 08, 2019 ...
FDA Approves Bonsity (teriparatide injection) to Treat Osteoporosis
Article Link: FDA Approves Bonsity (teriparatide injection) to Treat Osteoporosis SAN DIEGO, October 7, 2019 — Pfenex Inc. (NYSE American...
FDA Approves Aklief (trifarotene) Cream, a New Topical Retinoid for the Treatment of Acne
Article Link: FDA Approves Aklief (trifarotene) Cream, a New Topical Retinoid for the Treatment of Acne FORT WORTH, Texas – (October 4, 2...
FDA Approves Fasenra Pen (benralizumab) Pre-Filled Auto-Injector for Self-Administration
Article Link: FDA Approves Fasenra Pen (benralizumab) Pre-Filled Auto-Injector for Self-Administration October 4, 2019 — AstraZenec...
FDA Approves Descovy (emtricitabine and tenofovir alafenamide) for HIV Pre-Exposure Prophylaxis (PrEP)
Article Link: FDA Approves Descovy (emtricitabine and tenofovir alafenamide) for HIV Pre-Exposure Prophylaxis (PrEP) FOSTER CITY, Calif.&...
FDA Approves Label Update for Crysvita (burosumab) for the Treatment of X-Linked Hypophosphatemia (XLH) in Pediatric Patients 6 Months of Age and Older
Article Link: FDA Approves Label Update for Crysvita (burosumab) for the Treatment of X-Linked Hypophosphatemia (XLH) in Pediatric Patients 6 Months o...
FDA Approves Invokana (canagliflozin) to Treat Diabetic Kidney Disease (DKD) and Reduce the Risk of Hospitalization for Heart Failure in Patients with Type 2 Diabetes and DKD
Article Link: FDA Approves Invokana (canagliflozin) to Treat Diabetic Kidney Disease (DKD) and Reduce the Risk of Hospitalization for Heart Failure in...
